AB Biotek works with Magnitude Biosciences to accelerate probiotic development

Magnitude Biosciences partnered with AB Biotek Human Nutrition & Health (ABB HNH), the global leader in yeast probiotics and postbiotics. Recently we had the pleasure of hosting Maria Tintoré and Carlos de Lecea from AB Biotek at our lab in Sedgefield, UK.

There is growing evidence on how health problems and diseases are linked to a disruption of our microbiota. The development of new probiotics and other products targeting the microbiome are critical to improve human health.  

There are ethical challenges however in testing new probiotics in vivo. Most manufacturers rely on using mammals such as rodents to test whether their products can improve whole animal health.  Rodent studies not only pose ethical concerns but are often expensive and take a long time to generate high quality data. The nematode worm C. elegans has many of the cell types found in humans, as well as a short life cycle, and is thus a more ethical as well as faster solution to study the impact of probiotics on whole organism health. 

AB Biotek were seeking more ethical options for testing their products without compromising on the reliability of in vivo data. Magnitude Biosciences were the obvious partner for this work, providing a unique solution that generates high quality, rich, fast and reliable data quantifying the impact of probiotics, prebiotics, health supplements and drug compounds in whole organism health without the use of mammalian models.

Magnitude Biosciences worked with the AB Biotek HNH scientific team to design and implement novel techniques to measure the impact of combinations of yeast, bacteria and prebiotics on whole organism health more ethically.

You can read the full case study here showing how health supplement and probiotics manufacturers can ethically and more cost-effectively test their products in vivo:

Press Contact:

Jessica Evans jess@magnitudebiosciences.com

Related News

Magnitude Biosciences: Revolutionising Research
Contract research organisation Magnitude Biosciences is projecting significant growth as it looks to...Read More
Life Sciences consortium celebrate collective multi-million Biomedical Catalyst 2023 Innovate UK grant
Press Release: 24th July 2023 Photo:  From left to right: Prof Carrie Ambler, (LightOx) Dr Sam Whit...Read More
Magnitude Biosciences awarded grant to accelerate the identification of compounds that could slow ageing or treat age-related diseases
Photo: The Magnitude Biosciences Team May 2023, Sedgefield, United Kingdom Magnitude Biosciences Lim...Read More
AB Biotek works with Magnitude Biosciences to accelerate probiotic development
Magnitude Biosciences partnered with AB Biotek Human Nutrition & Health (ABB HNH), the global le...Read More
Pharmaceutical company Lundbeck in collaboration with Magnitude Biosciences on innovative new platform to test interventions for neurodegenerative disease
Lundbeck collaborates with Magnitude on innovate platform to test neurodegenerative disease interven...Read More
Magnitude Biosciences secures new investment to accelerate scaling of its specialist anti-ageing research services
Magnitude Biosciences Limited, a specialist provider of C. elegans research services to the longevit...Read More
Magnitude Biosciences Appoints New CEO Fozia Saleem to Drive Growth
North East UK Biotech Magnitude Biosciences announces new CEO, Fozia Saleem, to accelerate the growt...Read More
SMER28 Extends Healthspan – Revealing a New Target for Ageing Therapeutics
Biotech entrepreneur Ethan Perlstein works with Magnitude Biosciences to reveal a new target for age...Read More
Magnitude Biosciences CEO David Weinkove appointed new Chair of British Society for Research on Ageing
The British Society for the Research on Ageing (BSRA) announces its new Chair, biology of ageing res...Read More
Frontiers in Aging: Applying C. elegans to industrial drug discovery
Just published in Frontiers in Aging: Applying C. elegans to industrial drug discovery...Read More
Magnitude Biosciences, Perfectus Biomed Group and University of Kent Project Funded by National Biofilms Innovation Centre for Tackling and Exploiting Biofilms
The joint project for Magnitude Biosciences, Perfectus Biomed Group and the University of Kent aims ...Read More
Research on ageing leader Magnitude Biosciences expands its project delivery team to meet increased demand
Durham, UK - July 29, 2021 Magnitude Biosciences, the world’s leading commercial lab services prov...Read More
Magnitude Biosciences recognised in Developed in Durham as local success story
Magnitude Biosciences has been recognised by Developed in Durham....Read More
The worm angle on the taurine story: a route to the clinic by understanding mechanism
Dr Manish Chamoli in the lab of Gordon Lithgow at the Buck Institute (Right) David Weinkove, 15 June...Read More
Magnitude Biosciences secures its second round of funding to support its pre-clinical research services
Magnitude Biosciences secures its second round of funding to support its pre-clinical research servi...Read More
Magnitude Biosciences announces new hires to support continued growth
Durham, UK - March 2021 Magnitude Biosciences, a spin-out from Durham University and the leading con...Read More
Magnitude Biosciences secures UK government Future Fund to expand its workforce.
Durham, UK - August 2020 Research into new medicines is needed more than ever, but research labs acr...Read More
Magnitude Biosciences' new COVID-19 compatible laboratory is fully operational and we are ready to support your research
Magnitude Biosciences moves its unique COVID-19 compatibletechnology to a new lab at NETPark in Sedg...Read More

CONTACT US

Get in touch today to find out how we can 
support you to accelerate your research

CONTACT US

Get in touch today to find out how we can support you
to accelerate your research